Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + radiotherapy
- Development stage
- Unknown
- Lead developer
- Fondazione Italiana Linfomi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This treatment plan is a chemo-immunotherapy and radiotherapy regimen developed by the Fondazione Italiana Linfomi (FIL) for the treatment of diffuse large B-cell lymphoma (DLBCL). The protocol involves six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) administered in either 14-day or 21-day intervals. Following chemotherapy, patients undergo PET-scan restaging; those who remain PET-positive receive consolidation radiotherapy (36 Gy) to the site of initial bulky disease or residual PET-avid areas. This risk-adapted approach aims to maximize cure rates in low-risk DLBCL patients (aaIPI 0 with bulky disease or aaIPI 1) while using PET imaging to guide the necessity of local radiation therapy.
- Other names
- Treatment plan-Fondazione Italiana Linfomi - ETS-diffuse large B-cell lymphomaR-CHOP + RTR-CHOP-14 + RTR-CHOP-21 + RTR-CHOP followed by PET-oriented radiotherapy
02
Targets
Beyond the preview
Go deeper on rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone + radiotherapy.